Share-based Payment Arrangement, Expense of GRI Bio, Inc. from 31 Mar 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
GRI Bio, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2020 to 30 Sep 2025.
  • GRI Bio, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $465,000, a 1157% increase year-over-year.
  • GRI Bio, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $763,000, a 419% increase year-over-year.
  • GRI Bio, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $148,000, a 62% decline from 2023.
  • GRI Bio, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $388,000, a 1452% increase from 2022.
  • GRI Bio, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $25,000, a 96% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

GRI Bio, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $763,000 $465,000 +$428,000 +1157% 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025 2025 Q3
Q2 2025 $335,000 $41,000 +$4,000 +11% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $331,000 $220,000 +$183,000 +495% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $148,000 $37,000 +$1,000 +2.8% 01 Oct 2024 31 Dec 2024 10-K 14 Mar 2025 2024 FY
Q3 2024 $147,000 $37,000 -$289,000 -89% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025 2025 Q3
Q2 2024 $436,000 $37,000 +$24,000 +185% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $412,000 $37,000 +$24,000 +185% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $388,000 $36,000 +$192,000 01 Oct 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
Q3 2023 $196,000 $326,000 +$326,000 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $130,000 $13,000 +$13,000 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 $143,000 $13,000 -$168,000 -93% 01 Jan 2023 31 Mar 2023 10-Q 10 May 2024 2024 Q1
Q4 2022 $25,000 $156,000 -$782,000 -125% 01 Oct 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
Q3 2022 $807,000 $0 -$134,000 -100% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $941,000 $0 -$138,000 -100% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $1,079,000 $181,000 +$13,000 +7.7% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 $1,066,000 $626,000 +$472,000 +306% 01 Oct 2021 31 Dec 2021 10-K 14 Feb 2022 2021 FY
Q3 2021 $594,000 $134,000 +$82,000 +158% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022 2022 Q3
Q2 2021 $512,000 $138,000 +$110,000 +393% 01 Apr 2021 30 Jun 2021 10-Q 28 Jul 2022 2022 Q2
Q1 2021 $402,000 $168,000 +$133,000 +380% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $269,000 $154,000 01 Oct 2020 31 Dec 2020 10-K 14 Feb 2022 2021 FY
Q3 2020 $52,000 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $28,000 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $35,000 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1

GRI Bio, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $148,000 -$240,000 -62% 01 Jan 2024 31 Dec 2024 10-K 14 Mar 2025 2024 FY
2023 $388,000 +$363,000 +1452% 01 Jan 2023 31 Dec 2023 10-K 14 Mar 2025 2024 FY
2022 $25,000 -$601,000 -96% 01 Jan 2022 31 Dec 2022 10-K 28 Mar 2024 2023 FY
2021 $626,000 01 Jan 2021 31 Dec 2021 10-K 24 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.